Cargando…

Successful treatment of metastatic bladder cancer by gemcitabine‐cisplatin re‐challenge after pembrolizumab

INTRODUCTION: The advent of pembrolizumab has contributed to improved treatment outcomes for metastatic urothelial carcinoma, but the outcomes of treatments after second‐line treatment have not been established. CASE PRESENTATION: A 72‐year‐old man was referred to our hospital with gross hematuria a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arai, Takayuki, Takeuchi, Nobuyoshi, Sazuka, Tomokazu, Sato, Hiroaki, Imamura, Yusuke, Sakamoto, Shinichi, Komiya, Akira, Ichikawa, Tomohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560445/ https://www.ncbi.nlm.nih.gov/pubmed/34755056 http://dx.doi.org/10.1002/iju5.12348

Ejemplares similares

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

Relationship between Preoperative Pyuria and Bacille Calmette-Guerin Treatment in Intravesical Recurrence after Transurethral Resection of High-Risk, Non-Muscle Invasive, Bladder Carcinoma: A Retrospective Study of Human Data
por: Tsukamoto, Ryo, et al.
Publicado: (2023)

A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation
por: Arai, Yutaro, et al.
Publicado: (2023)

Expression of tertiary lymphoid structure in deferred cytoreductive nephrectomy of metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Sazuka, Tomokazu, et al.
Publicado: (2021)

Cushing's syndrome in pregnancy in which laparoscopic adrenalectomy was safely performed by a retroperitoneal approach
por: Takeuchi, Nobuyoshi, et al.
Publicado: (2023)

A case of ipsilateral three simultaneous renal cell carcinomas with different histologic types
por: Tanaka, Satoki, et al.
Publicado: (2023)

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel
por: Ando, Keisuke, et al.
Publicado: (2021)

Tumor Location and a Tumor Volume over 2.8 cc Predict the Prognosis for Japanese Localized Prostate Cancer
por: Baba, Haruki, et al.
Publicado: (2022)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
por: Kanesaka, Manato, et al.
Publicado: (2021)

Tumor localization by Prostate Imaging and Reporting and Data System (PI-RADS) version 2.1 predicts prognosis of prostate cancer after radical prostatectomy
por: Fujimoto, Ayumi, et al.
Publicado: (2023)

Left ileal conduit: A case report
por: Nakamura, Kazuyoshi, et al.
Publicado: (2019)

Machine-learning predicts time-series prognosis factors in metastatic prostate cancer patients treated with androgen deprivation therapy
por: Saito, Shinpei, et al.
Publicado: (2023)

Contribution of the L-Type Amino Acid Transporter Family in the Diagnosis and Treatment of Prostate Cancer
por: Zhao, Xue, et al.
Publicado: (2023)

Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma
por: Maimaiti, Maihulan, et al.
Publicado: (2020)

Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: a potential prognostic marker and therapeutic target
por: Yamada, Yasutaka, et al.
Publicado: (2019)

Apparent diffusion coefficient value for estimating clinicohistological factors in bladder cancer including infiltration style and lymphatic invasion
por: Fujimura, Masaaki, et al.
Publicado: (2016)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
por: Sazuka, Tomokazu, et al.
Publicado: (2015)

Pathological complete response of plasmacytoid variant bladder cancer to pembrolizumab following genomic analysis
por: Goto, Yusuke, et al.
Publicado: (2022)

Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma
por: Higuchi, Kosuke, et al.
Publicado: (2019)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Impact of relative dose intensity in gemcitabine–cisplatin chemotherapy for metastatic urothelial carcinoma
por: Kohei, Naoki, et al.
Publicado: (2018)

Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer
por: Sakamoto, Shinichi, et al.
Publicado: (2019)

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
por: Narayan, Vivek, et al.
Publicado: (2016)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022)

Treatment strategy for metastatic prostate cancer with extremely high PSA level: reconsidering the value of vintage therapy
por: Yamada, Yasutaka, et al.
Publicado: (2018)

Usefulness of Renal Autotransplantation for Radiotherapy-induced Renovascular Hypertension
por: Wakabayashi, Shinichi, et al.
Publicado: (2019)

Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review
por: Zhang, Wei, et al.
Publicado: (2023)

Capillary leak syndrome induced by neoadjuvant cisplatin and gemcitabine in a patient with bladder cancer
por: Massafra, Marco, et al.
Publicado: (2020)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder
por: Sung, Hyun Hwan, et al.
Publicado: (2022)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis
por: Yamada, Yasutaka, et al.
Publicado: (2017)

A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer
por: Doval, D C, et al.
Publicado: (2004)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Clinical course involving thrombocytosis and thrombocytopenia in a patient with bladder cancer treated with gemcitabine and cisplatin
por: Watanabe, Ayako, et al.
Publicado: (2021)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Radical resection of an initially unresectable intrahepatic cholangiocarcinoma after chemotherapy with using gemcitabine, cisplatin, and S-1: report of a case
por: Tsunematsu, Masashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_an5esgfq3tmtltskqn4gqkostm